NCT04894825 - Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

July 30, 2024

Study Completion Date

December 30, 2024

Conditions

Advanced Unresectable Solid Tumors

Interventions

DRUG

M108

Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)

DRUG

M108

IV infusion Q3W. (21-day cycles)

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing